Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: insmed.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/23/2024 | $48.00 | Buy | Truist |
2/15/2024 | $42.00 | Outperform | Wolfe Research |
12/8/2023 | $55.00 | Overweight | Wells Fargo |
11/20/2023 | $36.00 | Overweight | JP Morgan |
7/26/2023 | $50.00 | Buy | Guggenheim |
12/9/2022 | $28.00 | Buy | Mizuho |
12/7/2022 | $37.00 | Overweight | Barclays |
11/18/2022 | $39.00 | Buy | BofA Securities |
4/27/2022 | $56.00 | Buy | Goldman |
2/22/2022 | $57.00 → $52.00 | Outperform | SVB Leerink |
BRIDGEWATER, N.J., Oct. 4, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 52 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on October 1, 2024 to purchase an aggregate 106,160 shares of Insmed common stock at an exe
BRIDGEWATER, N.J., Sept. 6, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 60 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on September 3, 2024 to purchase an aggregate 137,140 shares of Insmed common stock at an
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023— —U.S. Launch Readiness for Brensocatib in Bronchiectasis Remains on Track with NDA Submission Expected in the Fourth Quarter of 2024— —Primary Endpoint for ENCORE Study of ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Infection Agreed Upon with U.S. FDA— —Company Reiterates 2024 Global ARIKAYCE Revenue Guidance in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J., Aug. 8, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first globa
BRIDGEWATER, N.J., Aug. 2, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 97 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on August 1, 2024 to purchase an aggregate 133,130 shares of Insmed common stock at an exercise price of $75.33 per share, the closing trad
BRIDGEWATER, N.J., July 29, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second-quarter 2024 financial results on Thursday, August 8, 2024. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, August 8, 2024, to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code 7862189. The call will also be webcas
BRIDGEWATER, N.J., July 5, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on July 1, 2024 to purchase an aggregate 38,110 shares of Insmed common stock at an exercise price of $66.34 per share, the closing trading
—New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo— —Additional Exploratory Endpoints to be Presented, Including FVC and Patient-Reported BEST Score— BRIDGEWATER, N.J., July 3, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that additional positive results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis, will be prese
BRIDGEWATER, N.J., June 27, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has called all $225 million aggregate principal amount of its outstanding 1.75% Convertible Senior Notes Due 2025 (the "Notes") (CUSIP No. 457669AA7) for redemption on August 9, 2024 (the "Redemption Date"). Insmed is redeeming the Notes as permitted under Section 11.03 of the indenture governing the Notes (the "Indenture"). Redemption Process The redemption price will be payable on the Redemption Date in cash and equal to 100% of the principal amount of the Notes outstand
BRIDGEWATER, N.J., June 7, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 15 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on June 3, 2024 to purchase an aggregate 49,340 shares of Insmed common stock at an exercise price of $55.94 per share, the closing trading
BRIDGEWATER, N.J., June 5, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024, at 10:00 a.m. ET. The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event. About Insmed Insmed Incorporated is a global biopharmaceutical company on a miss
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE® (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wise will also serve as a member of Insmed's Executive Committee. "We are thrilled to promote Drayton to Chief Commercial Officer at this critical inflecti
SC 13G - INSMED Inc (0001104506) (Subject)
SC 13G/A - INSMED Inc (0001104506) (Subject)
SC 13G - INSMED Inc (0001104506) (Subject)
SC 13G/A - INSMED Inc (0001104506) (Subject)
SC 13G/A - INSMED Inc (0001104506) (Subject)
SC 13G/A - INSMED Inc (0001104506) (Subject)
SC 13G/A - INSMED Inc (0001104506) (Subject)
SC 13G/A - INSMED Inc (0001104506) (Subject)
SC 13G - INSMED Inc (0001104506) (Subject)
SC 13G/A - INSMED Inc (0001104506) (Subject)
Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling
Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling
8-K - INSMED Inc (0001104506) (Filer)
10-Q - INSMED Inc (0001104506) (Filer)
8-K - INSMED Inc (0001104506) (Filer)
8-K - INSMED Inc (0001104506) (Filer)
8-K - INSMED Inc (0001104506) (Filer)
8-K - INSMED Inc (0001104506) (Filer)
8-K - INSMED Inc (0001104506) (Filer)
8-K - INSMED Inc (0001104506) (Filer)
424B5 - INSMED Inc (0001104506) (Filer)
8-K - INSMED Inc (0001104506) (Filer)
Truist initiated coverage of Insmed with a rating of Buy and set a new price target of $48.00
Wolfe Research initiated coverage of Insmed with a rating of Outperform and set a new price target of $42.00
Wells Fargo initiated coverage of Insmed with a rating of Overweight and set a new price target of $55.00
JP Morgan resumed coverage of Insmed with a rating of Overweight and set a new price target of $36.00
Guggenheim initiated coverage of Insmed with a rating of Buy and set a new price target of $50.00
Mizuho initiated coverage of Insmed with a rating of Buy and set a new price target of $28.00
Barclays initiated coverage of Insmed with a rating of Overweight and set a new price target of $37.00
BofA Securities initiated coverage of Insmed with a rating of Buy and set a new price target of $39.00
Goldman initiated coverage of Insmed with a rating of Buy and set a new price target of $56.00
SVB Leerink reiterated coverage of Insmed with a rating of Outperform and set a new price target of $52.00 from $57.00 previously
BRIDGEWATER, N.J., July 29, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second-quarter 2024 financial results on Thursday, August 8, 2024. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, August 8, 2024, to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code 7862189. The call will also be webcas
BRIDGEWATER, N.J., May 30, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for the Company's three most advanced programs, ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP). Shareholders and other interested parties may participate in the conference call by dialing (800) 715-9871 (U.S.) and (646) 307-1963 (international) and referencing access code 7504027. The call will also be webcast live on the Compa
—Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— —Treatment with Brensocatib Also Achieves Statistical Significance on Multiple Secondary Endpoints for Both Dosage Strengths Versus Placebo— —Brensocatib Well-Tolerated at Both Dosage Strengths— —Results from ASPEN Validate DPP1 Inhibition as New Mechanism of Action with Potential to Address Range of Neutrophil-Mediated Diseases— —Insmed Plans to Advance Quickly Toward U.S. Regulatory Filing, with Anticipated U.S. Launch in Mid-2025, Pending Approval— —Insmed to Host Investor Call at 8:00 a
—Conference Call to Take Place Tomorrow, Tuesday, May 28, 2024, at 8:00 am ET— BRIDGEWATER, N.J., May 27, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host a conference call and webcast tomorrow, Tuesday, May 28, 2024, at 8:00 am ET to discuss topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. The Company plans to issue a press release sharing the topline results at app
— ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter of 2023— —Company Reports Positive Topline Safety and Tolerability Data from the Phase 2 PH-ILD Study of TPIP with 79.3% of Patients Reaching the Maximum Dose of 640 µg by Week 5, with an Unexpectedly Positive and Robust Signal on the Exploratory Endpoint of Clinical Worsening— —Encouraging Blinded Data from First 40 Patients in Phase 2 PAH Study of TPIP, with Combined Active Treatment and Placebo Arms Showing Mean PVR Reduction of 19.9% and 6-Minute Walk Distance Improvement of 43 Meters— —Topline Data from the Phase 3 ASPEN
BRIDGEWATER, N.J., April 25, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first-quarter 2024 financial results on Thursday, May 9, 2024. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, May 9, 2024, to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code 7862189. The call will also be webcast live
BRIDGEWATER, N.J., Feb. 8, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth-quarter and full year 2023 financial results on Thursday, February 22, 2024. Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, February 22, 2024, to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S. and international) and referencing access code 7862189. The call will also be webc
BRIDGEWATER, N.J., Oct. 12, 2023 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third-quarter 2023 financial results on Thursday, October 26, 2023. Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, October 26, 2023, to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S. and international) and referencing access code 7862189. The call will also be webcast live on the
—QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcome Tool in Patients with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in ENCORE with No Modifications— —Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Larger Improvements in QOL-B Respiratory Score with Strong Trend Toward Significance vs. Macrolide-Based Background Regimen Alone— —ARIKAYCE-Treated Patients Had Nominally Statistically Significantly Higher Culture Conversion Rates at Month 7 vs. Comparator (78.8% vs. 47.1%, p=0.0010); Culture Conversion Began Earlier and Was More Likely to Persist Through Month 7 with ARIKAYCE Regimen— —No New or Unexpected Saf
-- ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 18% Growth Compared to the Second Quarter of 2022 -- -- Company Raises Full-Year 2023 Guidance Range for Global ARIKAYCE Revenues to $295 Million to $305 Million -- -- Topline Data from Post-Marketing ARISE Study of ARIKAYCE Expected in September of 2023 -- -- Blended Blinded Dose Titration Data for TPIP in PH-ILD and PAH Expected in Second Half of 2023 -- -- Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remains on Track to Read Out in the Second Quarter of 2024 -- BRIDGEWA
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 4.66% on an annualized basis producing an average annual return of 15.55%. Currently, Insmed has a market capitalization of $12.25 billion. Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $423.45 today based on a price of $75.12 for INSM at the time of writing. Insmed's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed b
Insmed's (NYSE:INSM) short percent of float has risen 10.99% since its last report. The company recently reported that it has 12.83 million shares sold short, which is 7.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.84 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is im
These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Rivian Automotive Inc (NASDAQ:RIVN) stock gained 21.37% in the last week following recent CPI Data. Additionally, the Department of Energy disclosed a $1.7 billion investment to transform 11 auto facilities that are either shut down or at risk into electric vehicle manufacturing plants and supply chain hubs. Enphase Energy Inc (NASDAQ:EMPH) stock upped 21.15% after the company announced residential and commercial products that can help solar projects qualify for the “Domestic Content Bonus Credit.” D.R. Horton, Inc. (NYSE:DHI) stock rocketed 12.53%. Shares of homebuilders, building com
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 4.84% on an annualized basis producing an average annual return of 15.98%. Currently, Insmed has a market capitalization of $12.37 billion. Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $4,261.94 today based on a price of $75.82 for INSM at the time of writing. Insmed's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and review
Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $60 to $85.
Goldman Sachs analyst Andrea Tan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $74 to $102.
Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $70 to $95.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B. Riley Securities raised the price target for Cinemark Holdings, Inc. (NYSE:CNK) from $16 to $27. B. Riley Securities analyst Eric Wold upgraded the stock from Neutral to Buy. Cinemark shares rose 1.7% to close at $21.73 on Friday. See how other analysts view this stock. Keefe, Bruyette & Woods raised the price target for American Express Company (NYSE:AXP) from $265 to $280. Keefe, Bruyette & Woods analyst Sanjay Sakhrani maintained an Outperform rating. American Express shares gained 0.3% to cl
HC Wainwright & Co. analyst Andrew Fein maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $70 to $90.